Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cyclacel Pharmaceuti
(NQ:
CYCC
)
1.030
UNCHANGED
Streaming Delayed Price
Updated: 3:59 PM EDT, Sep 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cyclacel Pharmaceuti
< Previous
1
2
Next >
Cyclacel Pharmaceuticals to Release First Quarter 2023 Financial Results
May 04, 2023
From
Cyclacel
Via
GlobeNewswire
Cyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax Credit
May 03, 2023
From
Cyclacel
Via
GlobeNewswire
Cyclacel Pharmaceuticals to Participate in March Investor Conferences
March 07, 2023
From
Cyclacel
Via
GlobeNewswire
Cyclacel Pharmaceuticals Reports Fourth Quarter And Full Year 2022 Financial Results And Provides Business Update
March 06, 2023
From
Cyclacel
Via
GlobeNewswire
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2022 Financial Results
February 27, 2023
From
Cyclacel
Via
GlobeNewswire
Cyclacel Pharmaceuticals to Participate in the 2023 BIO CEO & Investor Conference
January 30, 2023
From
Cyclacel
Via
GlobeNewswire
Cyclacel Pharmaceuticals Reviews 2022 Achievements and Announces Key Business Objectives for 2023
January 05, 2023
From
Cyclacel
Via
GlobeNewswire
Cyclacel Pharmaceuticals to Present at Biotech Showcase and Participate in a Corporate Access Event During the J.P. Morgan Healthcare Conference in January 2023
December 15, 2022
From
Cyclacel
Via
GlobeNewswire
Cyclacel Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
November 09, 2022
From
Cyclacel
Via
GlobeNewswire
Cyclacel Pharmaceuticals to Release Third Quarter 2022 Financial Results
November 03, 2022
From
Cyclacel
Via
GlobeNewswire
Cyclacel Reports Preliminary Data From Its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients With Solid Tumors and Lymphoma at ENA 2022
October 26, 2022
Daily dosing of fadraciclib was well tolerated; single agent activity observed across multiple tumor types including 2 PRs in T-cell lymphoma patients
From
Cyclacel
Via
GlobeNewswire
Cyclacel Hosting Research & Development Day
October 24, 2022
From
Cyclacel
Via
GlobeNewswire
Cyclacel Pharmaceuticals To Present Preliminary Data From The Phase 1/2 Clinical Trial Of Oral Fadraciclib At The 34th EORTC-NCI-AACR Symposium
October 13, 2022
- Preliminary Dose Escalation Data to be Presented on Novel CDK2/9 Inhibitor Fadraciclib in Patients with Solid Tumors and Lymphoma -
From
Cyclacel
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.